Drug Profile

ADU S100

Alternative Names: ADU-S100; MIW 815

Latest Information Update: 04 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aduro BioTech
Developer Chinook Therapeutics; Novartis
Class Antineoplastics; Nucleotides; Small molecules
Mechanism of Action Immunostimulants; STING1 protein stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Head and neck cancer
No development reported Lymphoma; Malignant melanoma; Solid tumours

Most Recent Events

26 Jun 2025 3900190 - updated - kdm, pd, HE
25 Apr 2025 Pharmacodynamics data from preclinical studies in Malignant melanoma presented at the 116^th Annual Meeting of the American Association for Cancer Research (AACR-2025)
11 Aug 2023 Chinook Therapeutics has been acquired by Novartis

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com